Because of the complexly structured and heterogeneous process as well as the paucity of experimental data, it is important to model how the dynamics of TGF-β-driven CTCs couples with the primary (mammary duct) and secondary (bone niche) cancers. This evidence concerns the gene TGFB1 and cancer.